Altimmune, Inc. — fact timeline

Altimmune, Inc. reported the first quarter ended March 31, 2026 results: net income $22.6 million, or $0.18 net loss per share.

“Altimmune, Inc. (the “Company”) issued a press release announcing the Company’s financial results for its first quarter ended March 31, 2026.”

Altimmune, Inc. entered into Underwriting Agreement with Leerink Partners LLC and Barclays Capital Inc., as representatives of the several underwriters valued at approximately $211.2 million (effective 2026-04-22).

“On April 22, 2026, Altimmune, Inc. (the “ Company ”) entered into an underwriting agreement (the “ Underwriting Agreement ”) with Leerink Partners LLC and Barclays Capital Inc., as representatives of the several underwriters named therein (the “ Underwriters ”) pursuant to which the Company agreed to issue and sell (i) 64,250,000 shares of the Company’s common stock, par value $0.0001 per share (the “ Common Stock ”) and accompanying common stock warrants to purchase shares of Common Stock (the “ Common Stock Warrants ”), to the Underwriters at a public offering price of $3.00 per share and (ii) in lieu of Common Stock to certain investors that so choose, pre-funded warrants (the “ Pre-Funded Warrants ” and together with the Common Stock Warrants, the “ Warrants ”) to purchase up to 10,750,000 shares of Common Stock to the Underwriters at a public offering price of $2.999 per Pre-Funded Warrant (the “ Offering ”).”

Altimmune, Inc.: Amended certificate of incorporation to increase authorized common stock from 200,000,000 to 400,000,000 shares (effective 2026-04-16).

“On April 16, 2026, Altimmune, Inc. (the “Company”) amended its Amended and Restated Certificate of Incorporation (the “Certificate of Incorporation”) by filing a Certificate of Amendment with the Secretary of State of Delaware. The Certificate of Amendment reflected an amendment to increase the number of authorized shares of common stock from 200,000,000 to 400,000,000”

Altimmune, Inc. reported financial results for the fourth quarter and full year ended December 31, 2025.

“On March 5, 2026, Altimmune, Inc. (the “Company”) issued a press release announcing the Company’s financial results for its fourth quarter and full year ended December 31, 2025.”

Altimmune, Inc. entered into Placement Agency Agreement with Titan Partners Group LLC, a division of American Capital Partners, LLC (effective 2026-01-27).

“The Company also entered into a Placement Agency Agreement with Titan Partners Group LLC, a division of American Capital Partners, LLC (“Titan Partners”) (the “Placement Agency Agreement,” and together with the Securities Purchase Agreement, the “Agreements”)”

Altimmune, Inc. entered into Securities Purchase Agreement with a new fundamental institutional investor valued at approximately $75 million (effective 2026-01-27).

“On January 27, 2026, Altimmune, Inc. (the “Company”) entered into a Securities Purchase Agreement with a new fundamental institutional investor (the “Securities Purchase Agreement”) relating to the issuance of 12,397,920 shares of the Company’s common stock, par value of $0.0001 per share (the “Common Stock”) and pre-funded warrants (the “Pre-Funded Warrants”)”

Altimmune, Inc. amended term loan of from an aggregate principal amount of $100.0 million to $125.0 million with Hercules Capital, Inc. at greater of (a) 9.70% per annum and (b) the prime rate as reported in The Wall St maturing 30 months from May 13, 2025.

“Company and Hercules. Under the terms of the Amendment, the lenders will, among other things, increase the availability under the Term Loan from an aggregate principal amount of $100.0 million to $125.0 million. The first Term Loan tranche was drawn down at closing on May 13, 2025 in an aggregate principal amount of $15.0 million. The second Term Loan tranche was drawn”

Altimmune, Inc. incurred term loan of $15.0 million with Hercules Capital, Inc. at greater of (a) the prime rate as reported in The Wall Street Journal plus 2.45% maturing June 1, 2029.

“first Term Loan tranche was made on the Closing Date in an aggregate principal amount of $15.0 million.”

Scott Harris departed as Chief Medical Officer at Altimmune, Inc..

“On February 24, 2025, the Company’s Chief Medical Officer, Dr. Scott Harris, provided the Company advance notice of his intention to retire from Altimmune as of February 28, 2026.”

Jerome Durso was appointed as Director at Altimmune, Inc..

“On February 24, 2025, the Board of Directors (the “Board”) of Altimmune, Inc. (the “Company”), upon the recommendation of the Nominating and Corporate Governance Committee of the Board, increased its size from eight to ten directors and appointed Teri Lawver and Jerome Durso as directors of the Board.”

Teri Lawver was appointed as Director at Altimmune, Inc..

“On February 24, 2025, the Board of Directors (the “Board”) of Altimmune, Inc. (the “Company”), upon the recommendation of the Nominating and Corporate Governance Committee of the Board, increased its size from eight to ten directors and appointed Teri Lawver and Jerome Durso as directors of the Board.”

Gregory Weaver was appointed as Chief Financial Officer at Altimmune, Inc..

“On November 11, 2024, Altimmune, Inc. (the “Company”) issued a press release announcing the decision of the Company’s Board of Directors (the “Board”) to appoint Mr. Gregory Weaver as the Company’s Chief Financial Officer (“CFO”), effective November 11, 2024.”

David J. Drutz departed as Director at Altimmune, Inc..

“On August 13, 2024, David J. Drutz, M.D. notified the Board of Directors (the “Board”) of Altimmune, Inc. (the “Company”) that he has decided not to stand for re-election to the Board at the Company’s 2024 Annual Meeting of Shareholders (the “Annual Meeting”).”

Andrew Shutterly was appointed as acting Chief Financial Officer at Altimmune, Inc..

“appointed Andrew Shutterly as acting Chief Financial Officer”

Richard Eisenstadt departed as Chief Financial Officer at Altimmune, Inc..

“following the unexpected death of Richard Eisenstadt, the Company’s Chief Financial Officer.”

Altimmune, Inc. reported the first quarter ended March 31, 2024 results: net income Net loss for the three months ended March 31, 2024 was $24.4 million, or $0.34 net loss per share, EPS $0.34 net loss per share.

“● Net loss for the three months ended March 31, 2024 was $24.4 million, or $0.34 net loss per share, compared to a net loss of $20.1 million, or $0.40 net loss per share, in the same period in 2023.”

Altimmune, Inc. reported financial results for the fourth quarter and full year ended December 31, 2023.

“Altimmune, Inc. (the “Company”) issued a press release announcing the Company’s financial results for its full year and fiscal quarter ended December 31, 2023.”

Altimmune, Inc. reported the three months ended September 30, 2023 results: net income $20.7 million, or $0.39 net loss per share, EPS $0.39 net loss per share.

“Net loss for the three months ended September 30, 2023 was $20.7 million, or $0.39 net loss per share, compared to a net loss of $23.5 million, or $0.48 net loss per share, in the same period in 2022.”

Altimmune, Inc. shareholders approved Vote to authorize the adjournment of the 2023 Annual Meeting to enable the Board of Directors to solicit additional proxies at the 2023-09-28 meeting.

“Proposal No. 5 : Vote to authorize the adjournment of the 2023 Annual Meeting to enable the Board of Directors to solicit additional proxies. The results were as follows: ​ ​ ​ ​ ​ For ​ Against ​ Abstain 27,712,554 ​ 6,744,992 104,432”

Altimmune, Inc. shareholders approved Advisory vote on the frequency with which the Company will hold a non-binding, advisory vote on the compensation of its named executive officers as disclosed in the Proxy Statement pursuant to the SEC's compensation rules at the 2023-09-28 meeting.

“Proposal No. 4 : Advisory vote on the frequency with which the Company will hold a non-binding, advisory vote on the compensation of its named executive officers as disclosed in the Proxy Statement pursuant to the SEC's compensation rules (referred to as the "frequency of say-on-pay" proposal). The results were as follows: ​ ​ ​ ​ ​ ​ ​ ​ ​ 1 Year ​ 2 Years ​ 3 Years ​ Abstain ​ Broker Non-Votes 21,595,590 ​ 80,595 352,096 133,179 12,400,518”

Altimmune, Inc. shareholders approved Advisory vote on the Compensation of the Company's named executive officers as disclosed in the Proxy Statement pursuant to the SEC's compensation rules at the 2023-09-28 meeting.

“Proposal No. 3 : Advisory vote on the Compensation of the Company's named executive officers as disclosed in the Proxy Statement pursuant to the SEC's compensation rules (referred to as the "say-on-pay" proposal). The results were as follows: ​ ​ ​ ​ ​ ​ ​ For ​ Against ​ Abstain ​ Broker Non-Votes 16,834,432 ​ 5,221,648 ​ 105,380 12,400,518”

Altimmune, Inc. shareholders approved Ratification of the appointment of Ernst & Young LLP as the Company's independent registered public accounting firm for the year ending December 31, 2023 at the 2023-09-28 meeting.

“Proposal No. 2 : Ratification of the appointment of Ernst & Young LLP as the Company's independent registered public accounting firm for the year ending December 31, 2023. The results were as follows: ​ ​ ​ ​ ​ For ​ Against ​ Abstain 34,318,768 ​ 153,149 90,061”

Altimmune, Inc. shareholders approved Election of Directors at the 2023-09-28 meeting.

“Proposal No. 1 : Election of Directors. The results were as follows: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Broker Director ​ For ​ Withhold ​ Non-Votes Mitchel Sayare, Ph.D., Chairman ​ 21,844,990 316,470 12,400,518 Vipin K. Garg, Ph.D. ​ 21,885,151 276,309 12,400,518 David J. Drutz, M.D. ​ 19,880,376 2,281,084 12,400,518 John M. Gill ​ 21,588,792 572,668 12,400,518 Philip L. Hodges ​ 21,810,125 351,335 12,400,518 Diane Jorkasky, M.D. ​ 21,824,133 337,327 12,400,518 Wayne Pisano ​ 19,385,875 2,775,585 12,400,518 Klaus O. Schafer, M.D., MPH 21,823,016 338,444 12,400,518 Catherine Sohn, Pharm D 21,912,287 249,173 12,400,518”

Altimmune, Inc. reported the three months ended June 30, 2023 results: net income Net loss for the three months ended June 30, 2023 was $16.1 million, or $0.32 net loss per share, EPS $0.32 net loss per share.

“Altimmune, Inc. (the “Company”) issued a press release announcing the Company’s financial results for its fiscal quarter ended June 30, 2023.”

Altimmune, Inc. reported three months ended March 31, 2023 results: net income $20.1 million, EPS $0.40 net loss per share.

“Net loss for the three months ended March 31, 2023 was $20.1 million, or $0.40 net loss per share, compared to a net loss of $19.4 million, or $0.44 net loss per share, in the same period in 2022.”

Catherine Sohn was appointed as Director at Altimmune, Inc..

“appointed Catherine Sohn, Pharm.D. as a director of the Company’s Board, effective March 23, 2023.”

Altimmune, Inc. reported the three months ended December 31, 2022 results: net income $21.7 million, EPS $0.43 net loss per share.

“Net loss for the three months ended December 31, 2022 was $21.7 million, or $0.43 net loss per share, compared to a net loss of $23.9 million, or $0.57 net loss per share, in the same period in 2021.”

Altimmune, Inc. reported financial results for three months ended September 30, 2022.

“Revenue was minimal for the three months ended September 30, 2022 compared to $0.2 million in the same period in 2021.”

Richard I. Eisenstadt was appointed as Chief Financial Officer at Altimmune, Inc..

“the Company issued a press release announcing the decision of the Board to appoint Mr. Richard I. Eisenstadt as the Company’s Chief Financial Officer (“CFO”), effective December 31, 2021.”

William Brown resigned as Chief Financial Officer at Altimmune, Inc..

“William Brown, the Chief Financial Officer, principal accounting officer and principal financial officer of Altimmune, Inc. (the “Company”), submitted notice to the Company’s Board of Directors (the “Board”) of his resignation, effective as of December 31, 2021.”